Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis
Arab Journal of Gastroenterology · 2018-09 · 19 (3) · 116-120
DOI: 10.1016/j.ajg.2018.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arab Journal of Gastroenterology, 2018-09. Verfasst von Tarek Youssef und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt. Hauptthemen laut MEDLINE: Severity of Illness Index. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND STUDY AIMS: Studies have found increased expression of IL-23 in inflamed and non-inflamed mucosa of patients with ulcerative colitis (UC). We hypothesized that serum interleukin-23 as a non-invasive test has a role in pathogenesis of ulcerative colitis disease and correlates with the disease severity. PATIENTS AND METHODS: Forty patients with biopsy proven ulcerative colitis, recruited from Ain Shams University hospitals were included. Forty healthy subjects matched in age and gender were also included in the study as a control group. Serum IL-23 level was quantified using quantitative ELISA technique (Enzyme linked Immunosorbent Assay). RESULTS: Patients with UC had higher level of interleukin 23 (234.5 ± 161 pg/mL) compared to control subjects (54.2 ± 15 pg/mL) and the level of IL-23 correlated with the disease severity. Cut off value of IL-23 at 68 pg/mL was the best to differentiate between cases and control subjects. Receiver operating characteristic curve (ROC) revealed that the best cut off for IL-23 to detect mild cases of ulcerative colitis was at105 pg/mL, to detect moderate cases at 200 pg/mL and to detect severe cases was at 270 pg/mL with sensitivity 80% to mild cases, 60% to moderate cases and 81% to severe cases. CONCLUSION: Our findings confirm the suggestion that IL-23 level measurement may be of value as a non-invasive test in the diagnosis and disease severity assessment in patients with UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
- Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt. Electronic address: emanfawzy@med.asu.edu.eg.
- Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Zitieren
APA
Youssef, T., Saleh, S. A., Rund, A., Montasser, I., Mohsen, M., & Hazem, O. (2018). Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis. Arab Journal of Gastroenterology, 19(3), 116-120. https://doi.org/10.1016/j.ajg.2018.09.003
Vancouver
Youssef T, Saleh SA, Rund A, Montasser I, Mohsen M, Hazem O. Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis. Arab Journal of Gastroenterology. 2018;19(3):116-120. doi:10.1016/j.ajg.2018.09.003
BibTeX
@article{Youssef2018,
author = {Youssef, Tarek and Saleh, Shereen A and Rund, Angie and Montasser, Iman and Mohsen, Manal and Hazem, Ola},
title = {Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis},
journal = {Arab Journal of Gastroenterology},
year = {2018},
volume = {19},
number = {3},
pages = {116--120},
doi = {10.1016/j.ajg.2018.09.003}
}
EUVIMED